Centessa Pharmaceuticals experienced a 30.7% increase in short interest in September, but analysts still upgraded their ratings.
Centessa Pharmaceuticals saw a 30.7% increase in short interest in September, totaling 1,960,000 shares, with a short-interest ratio of 3.3 days. Despite this, analysts have upgraded their ratings, with price targets ranging from $14 to $35. The stock closed at $16.09, down $0.57. Insider sales occurred in August, while several institutional investors increased their stakes. Overall, the company maintains a positive outlook from analysts.
October 16, 2024
3 Articles